Xanthogranulomatous pyelonephritis (XGP) and renal replacement lipomatosis (RRL) are severe, chronic, end-stage destructive renal processes typically driven by long-standing calculus obstruction. XGP is characterised by destructive granulomatous inflammation with pus/debris-filled calyces ('bear paw' sign) and aggressive retroperitoneal extension, whereas RRL involves extensive benign replacement of atrophic renal parenchyma by macroscopic adipose tissue.
I am presented with an abdominal radiograph, which demonstrates a large branching radiopaque staghorn calculus projecting over the right renal bed, accompanied by an enlarged renal soft-tissue shadow and compensatory hypertrophy of the left kidney. Moving to the contrast-enhanced CT of the abdomen, the right kidney is enlarged and non-functioning, containing the obstructing staghorn calculus within a contracted renal pelvis. The renal parenchyma is largely replaced by multiple rounded, low-attenuation fluid-density collections measuring 0 to +15 HU with peripheral rim enhancement, giving the classic 'bear paw' sign. There is marked thickening of Gerota's fascia with inflammatory stranding extending into the adjacent right psoas muscle, with no expansile renal vein tumour thrombus. The left kidney enhances and excretes normally. The primary diagnosis is diffuse xanthogranulomatous pyelonephritis secondary to chronic calculus obstruction. The main differential is renal replacement lipomatosis, which would instead demonstrate macroscopic fat attenuation of -20 to -100 HU, and renal cell carcinoma, which typically lacks a central staghorn calculus and exhibits hypervascular solid enhancement or tumour thrombus. I would compare with any previous imaging, if available, and refer this patient urgently to the urology team and request multi-disciplinary team review.
Urgent urology referral and MDT review with careful CT mapping of retroperitoneal fistulae.
Assuming low attenuation in XGP represents macroscopic fat rather than fluid/pus (0 to +15 HU from microscopic intracellular lipid), leading to confusion with renal replacement lipomatosis.
1. Which named CT sign is characteristic of diffuse xanthogranulomatous pyelonephritis?
2. How is xanthogranulomatous pyelonephritis differentiated from renal cell carcinoma on contrast-enhanced CT?
3. What CT attenuation values define the macroscopic adipose tissue seen in renal replacement lipomatosis?
4. What is the interpretive trap when evaluating the low-attenuation parenchymal areas in xanthogranulomatous pyelonephritis?
Sign in to keep track of the lessons you have done.